RESUMO
AIMS: Weight changes from a young age are known to be associated with poor life outcomes in the general population. However, little is known about the association between weight change from a young age and life expectancy in patients with chronic kidney disease (CKD). METHODS: Data of 2,806 nondialysis CKD patients who participated in the Fukuoka Kidney Disease Registry (FKR) Study, a multicenter observational study, were analyzed. The primary outcome was all-cause death, whereas the secondary outcome was cardiovascular mortality. The covariate of interest was weight change, defined as the difference between body weight at study enrollment and at 20 years old. Cox proportional-hazards models were used to estimate the risks of mortality for participants with weight changes of ≥ 5 or ï¼5 kg compared with those with stable weights. RESULTS: During the 5-year observation period, 243 participants died from all causes and 62 from cardiovascular disease. The risk of all-cause mortality in the weight-loss group was significantly higher than that in the stable-weight group (multivariable-adjusted hazard ratio, 2.11; 95% confidence interval [CI], 1.52-2.93). Conversely, the risk of cardiovascular mortality in the weight-loss group was significantly higher than that in the stable-weight group (multivariable-adjusted hazard ratio, 2.48; 95% CI, 1.32-4.64). However, no significant association was observed between weight gain and the risks of all-cause and cardiovascular mortalities. CONCLUSION: Weight loss from 20 years of age was found to be associated with higher risks of all-cause and cardiovascular mortalities in patients with CKD.
Assuntos
Doenças Cardiovasculares , Causas de Morte , Insuficiência Renal Crônica , Redução de Peso , Humanos , Masculino , Insuficiência Renal Crônica/mortalidade , Insuficiência Renal Crônica/complicações , Doenças Cardiovasculares/mortalidade , Doenças Cardiovasculares/etiologia , Feminino , Pessoa de Meia-Idade , Idoso , Adulto , Fatores de Risco , Aumento de Peso , Sistema de Registros , Seguimentos , Japão/epidemiologia , Adulto Jovem , Taxa de Sobrevida , Prognóstico , Modelos de Riscos ProporcionaisRESUMO
Immunodeficient patients are susceptible to systemic fungal infections; however, these rarely cause secondary peritonitis. A 66-year-old man with multiple myeloma and diabetes mellitus on continuous ambulatory peritoneal dialysis (CAPD) presented with cloudy ascitic fluid. He had been treated with corticosteroids for 1 month for Tolosa-Hunt syndrome. We diagnosed peritoneal dialysis-related peritonitis caused by Enterococcus avium, removed the CAPD catheter, and initiated intravenous ampicillin. Computed tomography (CT) revealed an intramural gastric mass and a thinning ascending colon wall. Four days later, follow-up contrast-enhanced CT showed penetration of the ascending colon and rupture of the ileocolic artery. Emergency open surgery revealed hemorrhagic infarction with mucormycosis. We initiated intravenous liposomal amphotericin B 20 days after admission; however, he died 55 days later. Anatomical abnormalities, such as gastrointestinal perforation, should be considered for peritonitis in immunodeficient patients. Gastrointestinal mucormycosis is rare but fatal, resulting from a delay in diagnosis and consequent gastrointestinal perforation. For an early diagnosis and a favorable clinical outcome, it is important to consider the risk factors for mucormycosis, including corticosteroid use, diabetes, end-stage kidney diseases.
Assuntos
Mucormicose , Micoses , Diálise Peritoneal Ambulatorial Contínua , Diálise Peritoneal , Peritonite , Idoso , Humanos , Masculino , Mucormicose/complicações , Mucormicose/diagnóstico , Micoses/tratamento farmacológico , Diálise Peritoneal/efeitos adversos , Diálise Peritoneal Ambulatorial Contínua/efeitos adversos , Peritonite/diagnóstico , Peritonite/tratamento farmacológico , Peritonite/etiologiaRESUMO
Plerixafor and bortezomib have recently been used in autologous stem cell collection to increase the amount of stem cells collected. However, no reports have described the combined use of plerixafor and bortezomib in cases of dialysis-dependent multiple myeloma. The dialysis-dependent multiple myeloma patient in the present study had a small amount of CD34-positive cells with plerixafor and filgrastim, and also with bortezomib and cyclophosphamide. However, by adding plerixafor to bortezomib and cyclophosphamide, collected CD34-positive cells were increased six-fold compared to the previous day. These findings suggest that the combination of plerixafor and bortezomib may be effective in those patients.
Assuntos
Fármacos Anti-HIV/uso terapêutico , Benzilaminas/uso terapêutico , Ciclamos/uso terapêutico , Mobilização de Células-Tronco Hematopoéticas/métodos , Mieloma Múltiplo/tratamento farmacológico , Mieloma Múltiplo/terapia , Diálise Renal/métodos , Fármacos Anti-HIV/farmacologia , Benzilaminas/farmacologia , Ciclamos/farmacologia , Feminino , Humanos , Pessoa de Meia-Idade , Mieloma Múltiplo/patologiaRESUMO
One way of increasing the energy density of lithium-ion batteries is to use electrode materials that exhibit high capacities owing to multielectron processes. Here, we report two novel materials, Li2TiS3 and Li3NbS4, which were mechanochemically synthesised at room temperature. When used as positive-electrode materials, Li2TiS3 and Li3NbS4 charged and discharged with high capacities of 425 mA h g(-1) and 386 mA h g(-1), respectively. These capacities correspond to those resulting from 2.5- and 3.5-electron processes. The average discharge voltage was approximately 2.2 V. It should be possible to prepare a number of high-capacity materials on the basis of the concept used to prepare Li2TiS3 and Li3NbS4.